Compare Tempus AI (TEM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs Tango Therapeutics Inc. — how do they compare? Tempus AI trades at $64.71 (market cap $12.40B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Tempus AI is far larger — about 3.3× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tempus AI for 23 Days and Tango Therapeutics Inc. for 0 Days on average.
| TEM | TNGX | |
|---|---|---|
Market Cap | $12.40B | $3.74B |
Volume | 6,036,503 | 3,438,781 |
Sector | Broad Market / Factor | Health |
52-Week High | $92.45 | $32.90 |
52-Week Low | $41.55 | $7.50 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $13.03B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $68.22, up 0.34% on the day, with a bullish technical signal despite negative profitability. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent FDA clearance for its ECG-MR AI product and multiple data licensing agreements highlight ongoing business development. Revenue growth is projected from $1.27 billion in 2025 to $1.4 billion in 2026, though net losses persist.
The outlook is supported by strong analyst consensus (64% buy ratings) and a $72.60 price target, suggesting modest upside. Key risks include sustained negative cash flow from operations, high valuation multiples, and insider selling. Investment appeal hinges on the company's ability to translate top-line growth into profitability amid competitive and execution challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
